Psoriasis - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 771 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Psoriasis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Psoriasis - Pipeline Review, H1 2016', provides an overview of the Psoriasis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psoriasis
- The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects
- The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Psoriasis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

Introduction 9
Psoriasis Overview 10
Therapeutics Development 11
Psoriasis - Therapeutics under Development by Companies 13
Psoriasis - Therapeutics under Investigation by Universities/Institutes 26
Psoriasis - Pipeline Products Glance 27
Psoriasis - Products under Development by Companies 31
Psoriasis - Products under Investigation by Universities/Institutes 49
Psoriasis - Companies Involved in Therapeutics Development 50
Psoriasis - Therapeutics Assessment 190
Drug Profiles 217
Psoriasis - Recent Pipeline Updates 562
Psoriasis - Dormant Projects 703
Psoriasis - Discontinued Products 729
Psoriasis - Product Development Milestones 734
Appendix 742

List of Tables

Number of Products under Development for Psoriasis, H1 2016 39
Number of Products under Development for Psoriasis - Comparative Analysis, H1 2016 40
Number of Products under Development by Companies, H1 2016 42
Number of Products under Development by Companies, H1 2016 (Contd..1) 43
Number of Products under Development by Companies, H1 2016 (Contd..2) 44
Number of Products under Development by Companies, H1 2016 (Contd..3) 45
Number of Products under Development by Companies, H1 2016 (Contd..4) 46
Number of Products under Development by Companies, H1 2016 (Contd..5) 47
Number of Products under Development by Companies, H1 2016 (Contd..6) 48
Number of Products under Development by Companies, H1 2016 (Contd..7) 49
Number of Products under Development by Companies, H1 2016 (Contd..8) 50
Number of Products under Development by Companies, H1 2016 (Contd..9) 51
Number of Products under Development by Companies, H1 2016 (Contd..10) 52
Number of Products under Development by Companies, H1 2016 (Contd..11) 53
Number of Products under Investigation by Universities/Institutes, H1 2016 54
Comparative Analysis by Late Stage Development, H1 2016 55
Comparative Analysis by Clinical Stage Development, H1 2016 56
Comparative Analysis by Early Stage Development, H1 2016 57
Comparative Analysis by Unknown Stage Development, H1 2016 58
Products under Development by Companies, H1 2016 59
Products under Development by Companies, H1 2016 (Contd..1) 60
Products under Development by Companies, H1 2016 (Contd..2) 61
Products under Development by Companies, H1 2016 (Contd..3) 62
Products under Development by Companies, H1 2016 (Contd..4) 63
Products under Development by Companies, H1 2016 (Contd..5) 64
Products under Development by Companies, H1 2016 (Contd..6) 65
Products under Development by Companies, H1 2016 (Contd..7) 66
Products under Development by Companies, H1 2016 (Contd..8) 67
Products under Development by Companies, H1 2016 (Contd..9) 68
Products under Development by Companies, H1 2016 (Contd..10) 69
Products under Development by Companies, H1 2016 (Contd..11) 70
Products under Development by Companies, H1 2016 (Contd..12) 71
Products under Development by Companies, H1 2016 (Contd..13) 72
Products under Development by Companies, H1 2016 (Contd..14) 73
Products under Development by Companies, H1 2016 (Contd..15) 74
Products under Development by Companies, H1 2016 (Contd..16) 75
Products under Development by Companies, H1 2016 (Contd..17) 76
Products under Investigation by Universities/Institutes, H1 2016 77
Psoriasis - Pipeline by 3SBio Inc., H1 2016 78
Psoriasis - Pipeline by 4SC AG, H1 2016 79
Psoriasis - Pipeline by Abeome Corporation, H1 2016 80
Psoriasis - Pipeline by AbGenomics International, Inc., H1 2016 81
Psoriasis - Pipeline by ADC Therapeutics Sarl, H1 2016 82
Psoriasis - Pipeline by Addex Therapeutics Ltd, H1 2016 83
Psoriasis - Pipeline by Advinus Therapeutics Ltd., H1 2016 84
Psoriasis - Pipeline by Affibody AB, H1 2016 85
Psoriasis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2016 86
Psoriasis - Pipeline by AlbireoPharma, H1 2016 87
Psoriasis - Pipeline by Almirall, S.A., H1 2016 88
Psoriasis - Pipeline by Amgen Inc., H1 2016 89
Psoriasis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 90
Psoriasis - Pipeline by AnaptysBio, Inc., H1 2016 91
Psoriasis - Pipeline by ApoPharma Inc., H1 2016 92
Psoriasis - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 93
Psoriasis - Pipeline by Argos Therapeutics, Inc., H1 2016 94
Psoriasis - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 95
Psoriasis - Pipeline by AstraZeneca Plc, H1 2016 96
Psoriasis - Pipeline by Athenex, Inc., H1 2016 97
Psoriasis - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 98
Psoriasis - Pipeline by Avexxin AS, H1 2016 99
Psoriasis - Pipeline by BIOCAD, H1 2016 100
Psoriasis - Pipeline by Biocon Limited, H1 2016 101
Psoriasis - Pipeline by BioLingus AG, H1 2016 102
Psoriasis - Pipeline by BioMAS Ltd., H1 2016 103
Psoriasis - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016 104
Psoriasis - Pipeline by Bionomics Limited, H1 2016 105
Psoriasis - Pipeline by Bionovis SA, H1 2016 106
Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 107
Psoriasis - Pipeline by Brickell Biotech, Inc., H1 2016 108
Psoriasis - Pipeline by Bristol-Myers Squibb Company, H1 2016 109
Psoriasis - Pipeline by C4X Discovery Holdings PLC, H1 2016 110
Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H1 2016 111
Psoriasis - Pipeline by Celgene Corporation, H1 2016 112
Psoriasis - Pipeline by Cellceutix Corporation, H1 2016 113
Psoriasis - Pipeline by Celltrion, Inc., H1 2016 114
Psoriasis - Pipeline by ChemoCentryx, Inc., H1 2016 115
Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H1 2016 116
Psoriasis - Pipeline by ChironWells GmbH, H1 2016 117
Psoriasis - Pipeline by Coherus BioSciences, Inc., H1 2016 118
Psoriasis - Pipeline by Compugen Ltd., H1 2016 119
Psoriasis - Pipeline by Convoy Therapeutics, Inc., H1 2016 120
Psoriasis - Pipeline by Creabilis SA, H1 2016 121
Psoriasis - Pipeline by Crescendo Biologics Limited, H1 2016 122
Psoriasis - Pipeline by Curapel Limited, H1 2016 123
Psoriasis - Pipeline by Delenex Therapeutics AG, H1 2016 124
Psoriasis - Pipeline by Domainex Limited, H1 2016 125
Psoriasis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H1 2016 126
Psoriasis - Pipeline by Effimune SAS, H1 2016 127
Psoriasis - Pipeline by Eli Lilly and Company, H1 2016 128
Psoriasis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 129
Psoriasis - Pipeline by Exicure, Inc., H1 2016 130
Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 131
Psoriasis - Pipeline by Forward Pharma A/S, H1 2016 132
Psoriasis - Pipeline by Galectin Therapeutics, Inc., H1 2016 133
Psoriasis - Pipeline by Gem Pharmaceuticals, LLC, H1 2016 134
Psoriasis - Pipeline by Gene Signal International SA, H1 2016 135
Psoriasis - Pipeline by Genentech, Inc., H1 2016 136
Psoriasis - Pipeline by Genor BioPharma Co., Ltd., H1 2016 137
Psoriasis - Pipeline by GlaxoSmithKline Plc, H1 2016 138
Psoriasis - Pipeline by GliaCure Inc., H1 2016 139
Psoriasis - Pipeline by GlycoMar Limited, H1 2016 140
Psoriasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 141
Psoriasis - Pipeline by Hydra Biosciences, Inc., H1 2016 142
Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 143
Psoriasis - Pipeline by Immune Pharmaceuticals Inc., H1 2016 144
Psoriasis - Pipeline by Immune Response BioPharma, Inc., H1 2016 145
Psoriasis - Pipeline by Immungenetics AG, H1 2016 146
Psoriasis - Pipeline by Innovent Biologics, Inc., H1 2016 147
Psoriasis - Pipeline by Invion Limited, H1 2016 148
Psoriasis - Pipeline by Jenrin Discovery, Inc., H1 2016 149
Psoriasis - Pipeline by Johnson & Johnson, H1 2016 150
Psoriasis - Pipeline by Kadmon Corporation, LLC, H1 2016 151
Psoriasis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 152
Psoriasis - Pipeline by Kineta, Inc., H1 2016 153
Psoriasis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 154
Psoriasis - Pipeline by Lead Pharma Holding B.V., H1 2016 155
Psoriasis - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 156
Psoriasis - Pipeline by LEO Pharma A/S, H1 2016 157
Psoriasis - Pipeline by Lipidor AB, H1 2016 158
Psoriasis - Pipeline by Lupin Limited, H1 2016 159
Psoriasis - Pipeline by Mabion SA, H1 2016 160
Psoriasis - Pipeline by mAbxience S.A., H1 2016 161
Psoriasis - Pipeline by Maruho Co., Ltd., H1 2016 162
Psoriasis - Pipeline by MediGene AG, H1 2016 163
Psoriasis - Pipeline by Merck KGaA, H1 2016 164
Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 165
Psoriasis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 166
Psoriasis - Pipeline by Mycenax Biotech Inc., H1 2016 167
Psoriasis - Pipeline by Neovacs SA, H1 2016 168
Psoriasis - Pipeline by Nimbus Therapeutics, LLC, H1 2016 169
Psoriasis - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 170
Psoriasis - Pipeline by Novan, Inc., H1 2016 171
Psoriasis - Pipeline by Novartis AG, H1 2016 172
Psoriasis - Pipeline by Nuevolution AB, H1 2016 173
Psoriasis - Pipeline by Oncobiologics, Inc., H1 2016 174
Psoriasis - Pipeline by Panacea Biotec Limited, H1 2016 175
Psoriasis - Pipeline by Pfizer Inc., H1 2016 176
Psoriasis - Pipeline by Pharis Biotec GmbH, H1 2016 177
Psoriasis - Pipeline by Pharmedartis GmbH, H1 2016 178
Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H1 2016 179
Psoriasis - Pipeline by PinCell srl, H1 2016 180
Psoriasis - Pipeline by Polichem S.A., H1 2016 181
Psoriasis - Pipeline by Promius Pharma, LLC, H1 2016 182
Psoriasis - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 183
Psoriasis - Pipeline by Prothena Corporation Plc, H1 2016 184
Psoriasis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 185
Psoriasis - Pipeline by RedHill Biopharma Ltd., H1 2016 186
Psoriasis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 187
Psoriasis - Pipeline by Sandoz International GmbH, H1 2016 188
Psoriasis - Pipeline by Sareum Holdings Plc, H1 2016 189
Psoriasis - Pipeline by Selvita S.A., H1 2016 190
Psoriasis - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2016 191
Psoriasis - Pipeline by Shulov Innovative Science Ltd., H1 2016 192
Psoriasis - Pipeline by Sigmoid Pharma Limited, H1 2016 193
Psoriasis - Pipeline by SignPath Pharma Inc, H1 2016 194
Psoriasis - Pipeline by Soligenix, Inc., H1 2016 195
Psoriasis - Pipeline by Spherium Biomed S.L., H1 2016 196
Psoriasis - Pipeline by Stemline Therapeutics, Inc., H1 2016 197
Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016 198
Psoriasis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 199
Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 200
Psoriasis - Pipeline by SWITCH Biotech LLC, H1 2016 201
Psoriasis - Pipeline by Syntrix Biosystems, Inc., H1 2016 202
Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 203
Psoriasis - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H1 2016 204
Psoriasis - Pipeline by Telormedix SA, H1 2016 205
Psoriasis - Pipeline by TetraLogic Pharmaceuticals, H1 2016 206
Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 207
Psoriasis - Pipeline by Therapeutic Proteins International, LLC, H1 2016 208
Psoriasis - Pipeline by Therapix Biosciences Ltd, H1 2016 209
Psoriasis - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 210
Psoriasis - Pipeline by UCB S.A., H1 2016 211
Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 212
Psoriasis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 213
Psoriasis - Pipeline by vTv Therapeutics LLC, H1 2016 214
Psoriasis - Pipeline by Wellstat Therapeutics Corporation, H1 2016 215
Psoriasis - Pipeline by Yuhan Corporation, H1 2016 216
Psoriasis - Pipeline by Ziarco Pharma Ltd, H1 2016 217
Assessment by Monotherapy Products, H1 2016 218
Assessment by Combination Products, H1 2016 219
Number of Products by Stage and Target, H1 2016 221
Number of Products by Stage and Mechanism of Action, H1 2016 233
Number of Products by Stage and Route of Administration, H1 2016 242
Number of Products by Stage and Molecule Type, H1 2016 244
Psoriasis Therapeutics - Recent Pipeline Updates, H1 2016 590
Psoriasis - Dormant Projects, H1 2016 731
Psoriasis - Dormant Projects (Contd..1), H1 2016 732
Psoriasis - Dormant Projects (Contd..2), H1 2016 733
Psoriasis - Dormant Projects (Contd..3), H1 2016 734
Psoriasis - Dormant Projects (Contd..4), H1 2016 735
Psoriasis - Dormant Projects (Contd..5), H1 2016 736
Psoriasis - Dormant Projects (Contd..6), H1 2016 737
Psoriasis - Dormant Projects (Contd..7), H1 2016 738
Psoriasis - Dormant Projects (Contd..8), H1 2016 739
Psoriasis - Dormant Projects (Contd..9), H1 2016 740
Psoriasis - Dormant Projects (Contd..10), H1 2016 741
Psoriasis - Dormant Projects (Contd..11), H1 2016 742
Psoriasis - Dormant Projects (Contd..12), H1 2016 743
Psoriasis - Dormant Projects (Contd..13), H1 2016 744
Psoriasis - Dormant Projects (Contd..14), H1 2016 745
Psoriasis - Dormant Projects (Contd..15), H1 2016 746
Psoriasis - Dormant Projects (Contd..16), H1 2016 747
Psoriasis - Dormant Projects (Contd..17), H1 2016 748
Psoriasis - Dormant Projects (Contd..18), H1 2016 749
Psoriasis - Dormant Projects (Contd..19), H1 2016 750
Psoriasis - Dormant Projects (Contd..20), H1 2016 751
Psoriasis - Dormant Projects (Contd..21), H1 2016 752
Psoriasis - Dormant Projects (Contd..22), H1 2016 753
Psoriasis - Dormant Projects (Contd..23), H1 2016 754
Psoriasis - Dormant Projects (Contd..24), H1 2016 755
Psoriasis - Dormant Projects (Contd..25), H1 2016 756
Psoriasis - Discontinued Products, H1 2016 757
Psoriasis - Discontinued Products (Contd..1), H1 2016 758
Psoriasis - Discontinued Products (Contd..2), H1 2016 759
Psoriasis - Discontinued Products (Contd..3), H1 2016 760
Psoriasis - Discontinued Products (Contd..4), H1 2016 761